nodes	percent_of_prediction	percent_of_DWPC	metapath
Diclofenac—migraine—Prednisone—systemic scleroderma	0.206	0.508	CpDpCtD
Diclofenac—osteoarthritis—Prednisone—systemic scleroderma	0.2	0.492	CpDpCtD
Diclofenac—UGT2B7—Mycophenolic acid—systemic scleroderma	0.0582	0.149	CbGbCtD
Diclofenac—UGT1A1—Mycophenolic acid—systemic scleroderma	0.0503	0.129	CbGbCtD
Diclofenac—UGT2B7—Mycophenolate mofetil—systemic scleroderma	0.0325	0.0831	CbGbCtD
Diclofenac—UGT1A1—Mycophenolate mofetil—systemic scleroderma	0.0281	0.0718	CbGbCtD
Diclofenac—SLCO1C1—Methotrexate—systemic scleroderma	0.024	0.0613	CbGbCtD
Diclofenac—CYP2C8—Mometasone—systemic scleroderma	0.0207	0.0529	CbGbCtD
Diclofenac—SLC22A6—Captopril—systemic scleroderma	0.0159	0.0406	CbGbCtD
Diclofenac—ALB—Captopril—systemic scleroderma	0.0135	0.0346	CbGbCtD
Diclofenac—SLC22A11—Methotrexate—systemic scleroderma	0.0124	0.0317	CbGbCtD
Diclofenac—ABCC4—Methotrexate—systemic scleroderma	0.0115	0.0295	CbGbCtD
Diclofenac—CYP1A2—Pentoxifylline—systemic scleroderma	0.0108	0.0276	CbGbCtD
Diclofenac—ALB—Mycophenolate mofetil—systemic scleroderma	0.0107	0.0272	CbGbCtD
Diclofenac—CYP1A2—Leflunomide—systemic scleroderma	0.0103	0.0264	CbGbCtD
Diclofenac—ABCB1—Lisinopril—systemic scleroderma	0.00946	0.0242	CbGbCtD
Diclofenac—CYP2C9—Leflunomide—systemic scleroderma	0.0093	0.0238	CbGbCtD
Diclofenac—ABCC1—Methotrexate—systemic scleroderma	0.00927	0.0237	CbGbCtD
Diclofenac—ALB—Prednisone—systemic scleroderma	0.00852	0.0218	CbGbCtD
Diclofenac—CYP2C8—Mycophenolate mofetil—systemic scleroderma	0.00824	0.0211	CbGbCtD
Diclofenac—SLC22A8—Methotrexate—systemic scleroderma	0.0072	0.0184	CbGbCtD
Diclofenac—ABCB1—Captopril—systemic scleroderma	0.00708	0.0181	CbGbCtD
Diclofenac—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.00557	0.0142	CbGbCtD
Diclofenac—CYP2C19—Prednisone—systemic scleroderma	0.00552	0.0141	CbGbCtD
Diclofenac—SLC22A6—Methotrexate—systemic scleroderma	0.00502	0.0128	CbGbCtD
Diclofenac—ABCB1—Prednisone—systemic scleroderma	0.00446	0.0114	CbGbCtD
Diclofenac—ALB—Methotrexate—systemic scleroderma	0.00427	0.0109	CbGbCtD
Diclofenac—CYP2C9—cardial valve—systemic scleroderma	0.00419	0.154	CbGeAlD
Diclofenac—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.00334	0.00854	CbGbCtD
Diclofenac—CYP3A4—Prednisone—systemic scleroderma	0.00267	0.00683	CbGbCtD
Diclofenac—ABCB1—Methotrexate—systemic scleroderma	0.00224	0.00571	CbGbCtD
Diclofenac—CXCR1—lung—systemic scleroderma	0.00141	0.0518	CbGeAlD
Diclofenac—PTGS2—skeletal joint—systemic scleroderma	0.00131	0.0483	CbGeAlD
Diclofenac—PLA2G2A—connective tissue—systemic scleroderma	0.000836	0.0308	CbGeAlD
Diclofenac—PLA2G2A—smooth muscle tissue—systemic scleroderma	0.000765	0.0281	CbGeAlD
Diclofenac—CXCL8—smooth muscle tissue—systemic scleroderma	0.000757	0.0278	CbGeAlD
Diclofenac—PTGS2—Fluocinonide—Mometasone—systemic scleroderma	0.00073	0.624	CbGdCrCtD
Diclofenac—KCNQ3—lung—systemic scleroderma	0.000665	0.0245	CbGeAlD
Diclofenac—TTR—connective tissue—systemic scleroderma	0.000631	0.0232	CbGeAlD
Diclofenac—PLA2G2A—digestive system—systemic scleroderma	0.000604	0.0222	CbGeAlD
Diclofenac—PTGS1—artery—systemic scleroderma	0.000575	0.0211	CbGeAlD
Diclofenac—PLA2G2A—tendon—systemic scleroderma	0.000574	0.0211	CbGeAlD
Diclofenac—ALOX5—connective tissue—systemic scleroderma	0.000572	0.021	CbGeAlD
Diclofenac—CYP2C18—digestive system—systemic scleroderma	0.000551	0.0203	CbGeAlD
Diclofenac—PTGS2—artery—systemic scleroderma	0.000549	0.0202	CbGeAlD
Diclofenac—ALOX5—smooth muscle tissue—systemic scleroderma	0.000523	0.0192	CbGeAlD
Diclofenac—UGT2B7—digestive system—systemic scleroderma	0.000508	0.0187	CbGeAlD
Diclofenac—PLA2G2A—lung—systemic scleroderma	0.000504	0.0186	CbGeAlD
Diclofenac—CXCL8—lung—systemic scleroderma	0.000499	0.0184	CbGeAlD
Diclofenac—SLC22A11—digestive system—systemic scleroderma	0.000495	0.0182	CbGeAlD
Diclofenac—PTGS1—endothelium—systemic scleroderma	0.000485	0.0179	CbGeAlD
Diclofenac—PTGS2—endothelium—systemic scleroderma	0.000464	0.0171	CbGeAlD
Diclofenac—TTR—digestive system—systemic scleroderma	0.000456	0.0168	CbGeAlD
Diclofenac—PTGS1—blood vessel—systemic scleroderma	0.000448	0.0165	CbGeAlD
Diclofenac—SCN4A—tendon—systemic scleroderma	0.000446	0.0164	CbGeAlD
Diclofenac—PTGS2—Fluticasone Propionate—Mometasone—systemic scleroderma	0.00044	0.376	CbGdCrCtD
Diclofenac—UGT1A1—digestive system—systemic scleroderma	0.000432	0.0159	CbGeAlD
Diclofenac—PTGS2—blood vessel—systemic scleroderma	0.000428	0.0157	CbGeAlD
Diclofenac—ALOX5—digestive system—systemic scleroderma	0.000413	0.0152	CbGeAlD
Diclofenac—TTR—lung—systemic scleroderma	0.000381	0.014	CbGeAlD
Diclofenac—ALOX5—lung—systemic scleroderma	0.000345	0.0127	CbGeAlD
Diclofenac—ABCC4—digestive system—systemic scleroderma	0.000282	0.0104	CbGeAlD
Diclofenac—ABCC4—tendon—systemic scleroderma	0.000268	0.00986	CbGeAlD
Diclofenac—ABCB1—blood vessel—systemic scleroderma	0.000265	0.00974	CbGeAlD
Diclofenac—CYP1A1—skin of body—systemic scleroderma	0.000236	0.00868	CbGeAlD
Diclofenac—ABCC4—lung—systemic scleroderma	0.000235	0.00865	CbGeAlD
Diclofenac—CYP2C19—digestive system—systemic scleroderma	0.000234	0.00862	CbGeAlD
Diclofenac—PTGS1—connective tissue—systemic scleroderma	0.000229	0.00845	CbGeAlD
Diclofenac—CYP2B6—skin of body—systemic scleroderma	0.000229	0.00844	CbGeAlD
Diclofenac—ABCC1—tendon—systemic scleroderma	0.000228	0.00841	CbGeAlD
Diclofenac—PTGS2—connective tissue—systemic scleroderma	0.000219	0.00807	CbGeAlD
Diclofenac—PTGS1—smooth muscle tissue—systemic scleroderma	0.00021	0.00773	CbGeAlD
Diclofenac—PTGS1—skin of body—systemic scleroderma	0.000207	0.00763	CbGeAlD
Diclofenac—PTGS2—smooth muscle tissue—systemic scleroderma	0.000201	0.00738	CbGeAlD
Diclofenac—ABCC1—lung—systemic scleroderma	0.0002	0.00738	CbGeAlD
Diclofenac—PTGS2—skin of body—systemic scleroderma	0.000198	0.00729	CbGeAlD
Diclofenac—CYP1A2—digestive system—systemic scleroderma	0.000191	0.00704	CbGeAlD
Diclofenac—CYP1A1—digestive system—systemic scleroderma	0.000189	0.00694	CbGeAlD
Diclofenac—CYP2B6—digestive system—systemic scleroderma	0.000183	0.00675	CbGeAlD
Diclofenac—CYP2C9—digestive system—systemic scleroderma	0.000182	0.00668	CbGeAlD
Diclofenac—CYP2E1—digestive system—systemic scleroderma	0.000172	0.00633	CbGeAlD
Diclofenac—PTGS1—digestive system—systemic scleroderma	0.000166	0.0061	CbGeAlD
Diclofenac—CYP2E1—tendon—systemic scleroderma	0.000164	0.00603	CbGeAlD
Diclofenac—CYP1A2—lung—systemic scleroderma	0.00016	0.00588	CbGeAlD
Diclofenac—PTGS2—digestive system—systemic scleroderma	0.000158	0.00583	CbGeAlD
Diclofenac—PTGS1—tendon—systemic scleroderma	0.000158	0.0058	CbGeAlD
Diclofenac—CYP1A1—lung—systemic scleroderma	0.000158	0.0058	CbGeAlD
Diclofenac—CYP2B6—lung—systemic scleroderma	0.000153	0.00563	CbGeAlD
Diclofenac—PTGS2—tendon—systemic scleroderma	0.000151	0.00555	CbGeAlD
Diclofenac—CYP2E1—lung—systemic scleroderma	0.000144	0.00529	CbGeAlD
Diclofenac—CYP3A4—digestive system—systemic scleroderma	0.000138	0.00509	CbGeAlD
Diclofenac—PTGS1—lung—systemic scleroderma	0.000138	0.00509	CbGeAlD
Diclofenac—PTGS2—lung—systemic scleroderma	0.000132	0.00487	CbGeAlD
Diclofenac—ABCB1—digestive system—systemic scleroderma	9.8e-05	0.00361	CbGeAlD
Diclofenac—ABCB1—lung—systemic scleroderma	8.18e-05	0.00301	CbGeAlD
Diclofenac—ALOX5—Selenium Micronutrient Network—IL1B—systemic scleroderma	8.03e-05	0.00289	CbGpPWpGaD
Diclofenac—CXCL8—IL-3 Signaling Pathway—TGFB1—systemic scleroderma	7.84e-05	0.00281	CbGpPWpGaD
Diclofenac—CXCL8—LPA receptor mediated events—MMP9—systemic scleroderma	7.68e-05	0.00276	CbGpPWpGaD
Diclofenac—CXCL8—SIDS Susceptibility Pathways—IL1A—systemic scleroderma	7.66e-05	0.00275	CbGpPWpGaD
Diclofenac—CXCR1—Signaling by GPCR—RHOB—systemic scleroderma	7.48e-05	0.00269	CbGpPWpGaD
Diclofenac—CXCR1—GPCR ligand binding—EDN1—systemic scleroderma	7.45e-05	0.00267	CbGpPWpGaD
Diclofenac—CYP1A2—Melatonin metabolism and effects—EDN1—systemic scleroderma	7.34e-05	0.00263	CbGpPWpGaD
Diclofenac—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL1B—systemic scleroderma	7.18e-05	0.00258	CbGpPWpGaD
Diclofenac—CXCL8—Corticotropin-releasing hormone—NOS3—systemic scleroderma	7.16e-05	0.00257	CbGpPWpGaD
Diclofenac—CXCL8—AP-1 transcription factor network—MMP9—systemic scleroderma	7.15e-05	0.00257	CbGpPWpGaD
Diclofenac—CXCL8—Allograft Rejection—IL1B—systemic scleroderma	6.88e-05	0.00247	CbGpPWpGaD
Diclofenac—PLA2G2A—Spinal Cord Injury—TGFB1—systemic scleroderma	6.73e-05	0.00242	CbGpPWpGaD
Diclofenac—CXCR1—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	6.68e-05	0.0024	CbGpPWpGaD
Diclofenac—CXCL8—Cellular Senescence—IL1A—systemic scleroderma	6.65e-05	0.00239	CbGpPWpGaD
Diclofenac—PLA2G2A—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	6.64e-05	0.00238	CbGpPWpGaD
Diclofenac—CXCL8—Spinal Cord Injury—CCL2—systemic scleroderma	6.58e-05	0.00236	CbGpPWpGaD
Diclofenac—CXCL8—Peptide ligand-binding receptors—EDN1—systemic scleroderma	6.58e-05	0.00236	CbGpPWpGaD
Diclofenac—ABCB1—Allograft Rejection—IL13—systemic scleroderma	6.51e-05	0.00234	CbGpPWpGaD
Diclofenac—ALOX5—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	6.43e-05	0.00231	CbGpPWpGaD
Diclofenac—CXCL8—Regulation of nuclear beta catenin signaling and target gene transcription—MMP9—systemic scleroderma	6.42e-05	0.00231	CbGpPWpGaD
Diclofenac—TTR—Extracellular matrix organization—MMP1—systemic scleroderma	6.34e-05	0.00228	CbGpPWpGaD
Diclofenac—CXCL8—AP-1 transcription factor network—TGFB1—systemic scleroderma	5.89e-05	0.00212	CbGpPWpGaD
Diclofenac—ABCB1—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	5.78e-05	0.00208	CbGpPWpGaD
Diclofenac—CXCR1—Signaling Pathways—SMAD7—systemic scleroderma	5.71e-05	0.00205	CbGpPWpGaD
Diclofenac—CXCL8—Toll-like Receptor Signaling Pathway—IL1B—systemic scleroderma	5.61e-05	0.00201	CbGpPWpGaD
Diclofenac—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TGFB1—systemic scleroderma	5.58e-05	0.002	CbGpPWpGaD
Diclofenac—CYP1A1—PPARA activates gene expression—CTGF—systemic scleroderma	5.54e-05	0.00199	CbGpPWpGaD
Diclofenac—TTR—Disease—SMAD7—systemic scleroderma	5.49e-05	0.00197	CbGpPWpGaD
Diclofenac—CXCL8—Senescence and Autophagy in Cancer—IL1B—systemic scleroderma	5.48e-05	0.00197	CbGpPWpGaD
Diclofenac—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CTGF—systemic scleroderma	5.43e-05	0.00195	CbGpPWpGaD
Diclofenac—CXCL8—Allograft Rejection—TGFB1—systemic scleroderma	5.35e-05	0.00192	CbGpPWpGaD
Diclofenac—ABCB1—Allograft Rejection—CTLA4—systemic scleroderma	5.24e-05	0.00188	CbGpPWpGaD
Diclofenac—KCNQ2—Axon guidance—MMP2—systemic scleroderma	5.11e-05	0.00183	CbGpPWpGaD
Diclofenac—KCNQ3—Axon guidance—MMP2—systemic scleroderma	5.11e-05	0.00183	CbGpPWpGaD
Diclofenac—CXCR1—GPCR ligand binding—CCL2—systemic scleroderma	5.09e-05	0.00183	CbGpPWpGaD
Diclofenac—CXCL8—Cellular responses to stress—IL1A—systemic scleroderma	5.03e-05	0.00181	CbGpPWpGaD
Diclofenac—TTR—Disease—TGFBI—systemic scleroderma	5.02e-05	0.0018	CbGpPWpGaD
Diclofenac—CXCL8—Spinal Cord Injury—IL1B—systemic scleroderma	4.99e-05	0.00179	CbGpPWpGaD
Diclofenac—ABCC4—Hemostasis—SELP—systemic scleroderma	4.94e-05	0.00177	CbGpPWpGaD
Diclofenac—TTR—Extracellular matrix organization—MMP2—systemic scleroderma	4.9e-05	0.00176	CbGpPWpGaD
Diclofenac—ALOX5—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	4.87e-05	0.00175	CbGpPWpGaD
Diclofenac—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	4.81e-05	0.000328	CcSEcCtD
Diclofenac—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	4.81e-05	0.000328	CcSEcCtD
Diclofenac—Insomnia—Lisinopril—systemic scleroderma	4.79e-05	0.000327	CcSEcCtD
Diclofenac—Discomfort—Mycophenolate mofetil—systemic scleroderma	4.79e-05	0.000327	CcSEcCtD
Diclofenac—Paraesthesia—Lisinopril—systemic scleroderma	4.76e-05	0.000325	CcSEcCtD
Diclofenac—ABCB1—HIF-1-alpha transcription factor network—EDN1—systemic scleroderma	4.76e-05	0.00171	CbGpPWpGaD
Diclofenac—Vomiting—Captopril—systemic scleroderma	4.76e-05	0.000325	CcSEcCtD
Diclofenac—Dry mouth—Mycophenolate mofetil—systemic scleroderma	4.74e-05	0.000323	CcSEcCtD
Diclofenac—CXCL8—Corticotropin-releasing hormone—TGFB1—systemic scleroderma	4.73e-05	0.0017	CbGpPWpGaD
Diclofenac—Dyspnoea—Lisinopril—systemic scleroderma	4.73e-05	0.000322	CcSEcCtD
Diclofenac—Rash—Captopril—systemic scleroderma	4.72e-05	0.000322	CcSEcCtD
Diclofenac—Dermatitis—Captopril—systemic scleroderma	4.72e-05	0.000322	CcSEcCtD
Diclofenac—Somnolence—Lisinopril—systemic scleroderma	4.71e-05	0.000322	CcSEcCtD
Diclofenac—CXCL8—Spinal Cord Injury—MMP9—systemic scleroderma	4.71e-05	0.00169	CbGpPWpGaD
Diclofenac—Headache—Captopril—systemic scleroderma	4.69e-05	0.00032	CcSEcCtD
Diclofenac—Confusional state—Mycophenolate mofetil—systemic scleroderma	4.68e-05	0.00032	CcSEcCtD
Diclofenac—Dyspepsia—Lisinopril—systemic scleroderma	4.67e-05	0.000318	CcSEcCtD
Diclofenac—Body temperature increased—Mycophenolic acid—systemic scleroderma	4.65e-05	0.000317	CcSEcCtD
Diclofenac—Abdominal pain—Mycophenolic acid—systemic scleroderma	4.65e-05	0.000317	CcSEcCtD
Diclofenac—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	4.64e-05	0.000317	CcSEcCtD
Diclofenac—Oedema—Mycophenolate mofetil—systemic scleroderma	4.64e-05	0.000317	CcSEcCtD
Diclofenac—Asthma—Methotrexate—systemic scleroderma	4.63e-05	0.000316	CcSEcCtD
Diclofenac—Infection—Mycophenolate mofetil—systemic scleroderma	4.61e-05	0.000315	CcSEcCtD
Diclofenac—ABCC4—Hemostasis—RHOB—systemic scleroderma	4.61e-05	0.00166	CbGpPWpGaD
Diclofenac—Decreased appetite—Lisinopril—systemic scleroderma	4.61e-05	0.000314	CcSEcCtD
Diclofenac—PTGS1—Selenium Micronutrient Network—CCL2—systemic scleroderma	4.59e-05	0.00165	CbGpPWpGaD
Diclofenac—Eosinophilia—Methotrexate—systemic scleroderma	4.58e-05	0.000313	CcSEcCtD
Diclofenac—Gastrointestinal disorder—Lisinopril—systemic scleroderma	4.58e-05	0.000312	CcSEcCtD
Diclofenac—Fatigue—Lisinopril—systemic scleroderma	4.57e-05	0.000312	CcSEcCtD
Diclofenac—Shock—Mycophenolate mofetil—systemic scleroderma	4.57e-05	0.000312	CcSEcCtD
Diclofenac—ALB—Vitamin B12 Metabolism—CCL2—systemic scleroderma	4.56e-05	0.00164	CbGpPWpGaD
Diclofenac—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	4.55e-05	0.000311	CcSEcCtD
Diclofenac—ABCC4—Ectoderm Differentiation—CCL2—systemic scleroderma	4.55e-05	0.00163	CbGpPWpGaD
Diclofenac—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	4.55e-05	0.00031	CcSEcCtD
Diclofenac—Hypersensitivity—Leflunomide—systemic scleroderma	4.55e-05	0.00031	CcSEcCtD
Diclofenac—Pancreatitis—Methotrexate—systemic scleroderma	4.54e-05	0.00031	CcSEcCtD
Diclofenac—Constipation—Lisinopril—systemic scleroderma	4.53e-05	0.000309	CcSEcCtD
Diclofenac—Pain—Lisinopril—systemic scleroderma	4.53e-05	0.000309	CcSEcCtD
Diclofenac—Tachycardia—Mycophenolate mofetil—systemic scleroderma	4.53e-05	0.000309	CcSEcCtD
Diclofenac—Skin disorder—Mycophenolate mofetil—systemic scleroderma	4.51e-05	0.000308	CcSEcCtD
Diclofenac—Bradycardia—Prednisone—systemic scleroderma	4.51e-05	0.000308	CcSEcCtD
Diclofenac—CXCL8—Peptide ligand-binding receptors—CCL2—systemic scleroderma	4.5e-05	0.00162	CbGpPWpGaD
Diclofenac—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	4.49e-05	0.000306	CcSEcCtD
Diclofenac—Diarrhoea—Azathioprine—systemic scleroderma	4.47e-05	0.000305	CcSEcCtD
Diclofenac—Haemoglobin—Prednisone—systemic scleroderma	4.45e-05	0.000304	CcSEcCtD
Diclofenac—Nausea—Captopril—systemic scleroderma	4.45e-05	0.000303	CcSEcCtD
Diclofenac—Abdominal discomfort—Methotrexate—systemic scleroderma	4.44e-05	0.000303	CcSEcCtD
Diclofenac—Haemorrhage—Prednisone—systemic scleroderma	4.43e-05	0.000302	CcSEcCtD
Diclofenac—Anorexia—Mycophenolate mofetil—systemic scleroderma	4.43e-05	0.000302	CcSEcCtD
Diclofenac—Asthenia—Leflunomide—systemic scleroderma	4.43e-05	0.000302	CcSEcCtD
Diclofenac—CXCR1—Signaling Pathways—RHOB—systemic scleroderma	4.42e-05	0.00159	CbGpPWpGaD
Diclofenac—CXCL8—Class A/1 (Rhodopsin-like receptors)—EDN1—systemic scleroderma	4.41e-05	0.00158	CbGpPWpGaD
Diclofenac—Hallucination—Prednisone—systemic scleroderma	4.41e-05	0.000301	CcSEcCtD
Diclofenac—Pancytopenia—Methotrexate—systemic scleroderma	4.39e-05	0.0003	CcSEcCtD
Diclofenac—CXCL8—Regulation of toll-like receptor signaling pathway—IL1B—systemic scleroderma	4.38e-05	0.00157	CbGpPWpGaD
Diclofenac—Feeling abnormal—Lisinopril—systemic scleroderma	4.37e-05	0.000298	CcSEcCtD
Diclofenac—Pruritus—Leflunomide—systemic scleroderma	4.36e-05	0.000298	CcSEcCtD
Diclofenac—Hypotension—Mycophenolate mofetil—systemic scleroderma	4.34e-05	0.000296	CcSEcCtD
Diclofenac—Gastrointestinal pain—Lisinopril—systemic scleroderma	4.33e-05	0.000296	CcSEcCtD
Diclofenac—ALB—Platelet activation, signaling and aggregation—SELP—systemic scleroderma	4.33e-05	0.00156	CbGpPWpGaD
Diclofenac—Dysuria—Methotrexate—systemic scleroderma	4.33e-05	0.000295	CcSEcCtD
Diclofenac—Dizziness—Azathioprine—systemic scleroderma	4.32e-05	0.000295	CcSEcCtD
Diclofenac—ABCB1—Allograft Rejection—HLA-DQB1—systemic scleroderma	4.31e-05	0.00155	CbGpPWpGaD
Diclofenac—Upper respiratory tract infection—Methotrexate—systemic scleroderma	4.3e-05	0.000293	CcSEcCtD
Diclofenac—Erectile dysfunction—Methotrexate—systemic scleroderma	4.26e-05	0.000291	CcSEcCtD
Diclofenac—CXCL8—Senescence and Autophagy in Cancer—TGFB1—systemic scleroderma	4.26e-05	0.00153	CbGpPWpGaD
Diclofenac—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	4.23e-05	0.000289	CcSEcCtD
Diclofenac—Photosensitivity reaction—Methotrexate—systemic scleroderma	4.22e-05	0.000288	CcSEcCtD
Diclofenac—Asthenia—Mycophenolic acid—systemic scleroderma	4.22e-05	0.000288	CcSEcCtD
Diclofenac—Diarrhoea—Leflunomide—systemic scleroderma	4.22e-05	0.000288	CcSEcCtD
Diclofenac—Urticaria—Lisinopril—systemic scleroderma	4.21e-05	0.000287	CcSEcCtD
Diclofenac—CXCR1—GPCR downstream signaling—EDN1—systemic scleroderma	4.21e-05	0.00151	CbGpPWpGaD
Diclofenac—Insomnia—Mycophenolate mofetil—systemic scleroderma	4.2e-05	0.000287	CcSEcCtD
Diclofenac—ABCC4—Hemostasis—CSK—systemic scleroderma	4.2e-05	0.00151	CbGpPWpGaD
Diclofenac—PTGS2—Spinal Cord Injury—IL1A—systemic scleroderma	4.19e-05	0.00151	CbGpPWpGaD
Diclofenac—Body temperature increased—Lisinopril—systemic scleroderma	4.19e-05	0.000286	CcSEcCtD
Diclofenac—Abdominal pain—Lisinopril—systemic scleroderma	4.19e-05	0.000286	CcSEcCtD
Diclofenac—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	4.17e-05	0.000285	CcSEcCtD
Diclofenac—CXCR1—Signaling Pathways—HSPG2—systemic scleroderma	4.17e-05	0.0015	CbGpPWpGaD
Diclofenac—Pruritus—Mycophenolic acid—systemic scleroderma	4.16e-05	0.000284	CcSEcCtD
Diclofenac—Vomiting—Azathioprine—systemic scleroderma	4.15e-05	0.000283	CcSEcCtD
Diclofenac—Pneumonia—Methotrexate—systemic scleroderma	4.15e-05	0.000283	CcSEcCtD
Diclofenac—ABCC4—Platelet degranulation—TGFB1—systemic scleroderma	4.15e-05	0.00149	CbGpPWpGaD
Diclofenac—Eye disorder—Prednisone—systemic scleroderma	4.14e-05	0.000283	CcSEcCtD
Diclofenac—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	4.14e-05	0.000283	CcSEcCtD
Diclofenac—Somnolence—Mycophenolate mofetil—systemic scleroderma	4.13e-05	0.000282	CcSEcCtD
Diclofenac—Drowsiness—Methotrexate—systemic scleroderma	4.13e-05	0.000281	CcSEcCtD
Diclofenac—Infestation—Methotrexate—systemic scleroderma	4.13e-05	0.000281	CcSEcCtD
Diclofenac—Infestation NOS—Methotrexate—systemic scleroderma	4.13e-05	0.000281	CcSEcCtD
Diclofenac—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL1B—systemic scleroderma	4.12e-05	0.00148	CbGpPWpGaD
Diclofenac—Rash—Azathioprine—systemic scleroderma	4.12e-05	0.000281	CcSEcCtD
Diclofenac—Dermatitis—Azathioprine—systemic scleroderma	4.12e-05	0.000281	CcSEcCtD
Diclofenac—Depression—Methotrexate—systemic scleroderma	4.11e-05	0.000281	CcSEcCtD
Diclofenac—Flushing—Prednisone—systemic scleroderma	4.11e-05	0.000281	CcSEcCtD
Diclofenac—ABCB1—Allograft Rejection—IL1A—systemic scleroderma	4.1e-05	0.00147	CbGpPWpGaD
Diclofenac—Headache—Azathioprine—systemic scleroderma	4.09e-05	0.000279	CcSEcCtD
Diclofenac—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	4.09e-05	0.000279	CcSEcCtD
Diclofenac—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	4.09e-05	0.000279	CcSEcCtD
Diclofenac—Dizziness—Leflunomide—systemic scleroderma	4.08e-05	0.000278	CcSEcCtD
Diclofenac—ABCB1—Allograft Rejection—CD40LG—systemic scleroderma	4.07e-05	0.00146	CbGpPWpGaD
Diclofenac—Renal failure—Methotrexate—systemic scleroderma	4.06e-05	0.000277	CcSEcCtD
Diclofenac—ALB—Platelet activation, signaling and aggregation—RHOB—systemic scleroderma	4.05e-05	0.00145	CbGpPWpGaD
Diclofenac—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	4.04e-05	0.000275	CcSEcCtD
Diclofenac—Diarrhoea—Mycophenolic acid—systemic scleroderma	4.03e-05	0.000275	CcSEcCtD
Diclofenac—CXCR1—Signaling Pathways—CSK—systemic scleroderma	4.03e-05	0.00145	CbGpPWpGaD
Diclofenac—Stomatitis—Methotrexate—systemic scleroderma	4.02e-05	0.000274	CcSEcCtD
Diclofenac—Angiopathy—Prednisone—systemic scleroderma	4.02e-05	0.000274	CcSEcCtD
Diclofenac—Conjunctivitis—Methotrexate—systemic scleroderma	4.01e-05	0.000274	CcSEcCtD
Diclofenac—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	4.01e-05	0.000274	CcSEcCtD
Diclofenac—TTR—Disease—HSPG2—systemic scleroderma	4.01e-05	0.00144	CbGpPWpGaD
Diclofenac—Immune system disorder—Prednisone—systemic scleroderma	4e-05	0.000273	CcSEcCtD
Diclofenac—CXCL8—SIDS Susceptibility Pathways—IL1B—systemic scleroderma	3.99e-05	0.00143	CbGpPWpGaD
Diclofenac—Constipation—Mycophenolate mofetil—systemic scleroderma	3.97e-05	0.000271	CcSEcCtD
Diclofenac—Pain—Mycophenolate mofetil—systemic scleroderma	3.97e-05	0.000271	CcSEcCtD
Diclofenac—Arrhythmia—Prednisone—systemic scleroderma	3.96e-05	0.00027	CcSEcCtD
Diclofenac—Sweating—Methotrexate—systemic scleroderma	3.96e-05	0.00027	CcSEcCtD
Diclofenac—ABCC4—Response to elevated platelet cytosolic Ca2+—TGFB1—systemic scleroderma	3.95e-05	0.00142	CbGpPWpGaD
Diclofenac—ABCC4—Hemostasis—ITGAM—systemic scleroderma	3.95e-05	0.00142	CbGpPWpGaD
Diclofenac—Haematuria—Methotrexate—systemic scleroderma	3.93e-05	0.000268	CcSEcCtD
Diclofenac—Vomiting—Leflunomide—systemic scleroderma	3.92e-05	0.000268	CcSEcCtD
Diclofenac—Alopecia—Prednisone—systemic scleroderma	3.92e-05	0.000267	CcSEcCtD
Diclofenac—Hypersensitivity—Lisinopril—systemic scleroderma	3.91e-05	0.000266	CcSEcCtD
Diclofenac—Hepatobiliary disease—Methotrexate—systemic scleroderma	3.9e-05	0.000266	CcSEcCtD
Diclofenac—PLA2G2A—Metabolism—HSPG2—systemic scleroderma	3.9e-05	0.0014	CbGpPWpGaD
Diclofenac—Dizziness—Mycophenolic acid—systemic scleroderma	3.89e-05	0.000266	CcSEcCtD
Diclofenac—Epistaxis—Methotrexate—systemic scleroderma	3.89e-05	0.000265	CcSEcCtD
Diclofenac—Rash—Leflunomide—systemic scleroderma	3.89e-05	0.000265	CcSEcCtD
Diclofenac—Dermatitis—Leflunomide—systemic scleroderma	3.89e-05	0.000265	CcSEcCtD
Diclofenac—Mental disorder—Prednisone—systemic scleroderma	3.88e-05	0.000265	CcSEcCtD
Diclofenac—Nausea—Azathioprine—systemic scleroderma	3.88e-05	0.000265	CcSEcCtD
Diclofenac—CXCL8—Spinal Cord Injury—TGFB1—systemic scleroderma	3.88e-05	0.00139	CbGpPWpGaD
Diclofenac—SCN4A—Axon guidance—MMP2—systemic scleroderma	3.87e-05	0.00139	CbGpPWpGaD
Diclofenac—TTR—Disease—CSK—systemic scleroderma	3.87e-05	0.00139	CbGpPWpGaD
Diclofenac—Headache—Leflunomide—systemic scleroderma	3.86e-05	0.000264	CcSEcCtD
Diclofenac—Erythema—Prednisone—systemic scleroderma	3.86e-05	0.000263	CcSEcCtD
Diclofenac—Malnutrition—Prednisone—systemic scleroderma	3.86e-05	0.000263	CcSEcCtD
Diclofenac—Agranulocytosis—Methotrexate—systemic scleroderma	3.85e-05	0.000263	CcSEcCtD
Diclofenac—TTR—Signaling Pathways—SMAD7—systemic scleroderma	3.85e-05	0.00138	CbGpPWpGaD
Diclofenac—KCNQ3—Axon guidance—MMP9—systemic scleroderma	3.84e-05	0.00138	CbGpPWpGaD
Diclofenac—KCNQ2—Axon guidance—MMP9—systemic scleroderma	3.84e-05	0.00138	CbGpPWpGaD
Diclofenac—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	3.83e-05	0.000261	CcSEcCtD
Diclofenac—CXCR1—Signaling by GPCR—EDN1—systemic scleroderma	3.82e-05	0.00137	CbGpPWpGaD
Diclofenac—Asthenia—Lisinopril—systemic scleroderma	3.8e-05	0.000259	CcSEcCtD
Diclofenac—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	3.8e-05	0.000259	CcSEcCtD
Diclofenac—Pruritus—Lisinopril—systemic scleroderma	3.75e-05	0.000256	CcSEcCtD
Diclofenac—Vomiting—Mycophenolic acid—systemic scleroderma	3.74e-05	0.000255	CcSEcCtD
Diclofenac—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—CTGF—systemic scleroderma	3.74e-05	0.00134	CbGpPWpGaD
Diclofenac—Haemoglobin—Methotrexate—systemic scleroderma	3.72e-05	0.000254	CcSEcCtD
Diclofenac—CXCL8—GPCR downstream signaling—RHOB—systemic scleroderma	3.72e-05	0.00134	CbGpPWpGaD
Diclofenac—ALB—Folate Metabolism—CCL2—systemic scleroderma	3.71e-05	0.00133	CbGpPWpGaD
Diclofenac—Rash—Mycophenolic acid—systemic scleroderma	3.71e-05	0.000253	CcSEcCtD
Diclofenac—Dermatitis—Mycophenolic acid—systemic scleroderma	3.71e-05	0.000253	CcSEcCtD
Diclofenac—Haemorrhage—Methotrexate—systemic scleroderma	3.7e-05	0.000253	CcSEcCtD
Diclofenac—Hepatitis—Methotrexate—systemic scleroderma	3.7e-05	0.000253	CcSEcCtD
Diclofenac—Urticaria—Mycophenolate mofetil—systemic scleroderma	3.69e-05	0.000252	CcSEcCtD
Diclofenac—Headache—Mycophenolic acid—systemic scleroderma	3.69e-05	0.000252	CcSEcCtD
Diclofenac—TTR—Extracellular matrix organization—MMP9—systemic scleroderma	3.69e-05	0.00132	CbGpPWpGaD
Diclofenac—ALB—Platelet activation, signaling and aggregation—CSK—systemic scleroderma	3.69e-05	0.00132	CbGpPWpGaD
Diclofenac—Pharyngitis—Methotrexate—systemic scleroderma	3.68e-05	0.000251	CcSEcCtD
Diclofenac—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	3.67e-05	0.000251	CcSEcCtD
Diclofenac—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	3.67e-05	0.000251	CcSEcCtD
Diclofenac—Nausea—Leflunomide—systemic scleroderma	3.66e-05	0.00025	CcSEcCtD
Diclofenac—Urinary tract disorder—Methotrexate—systemic scleroderma	3.66e-05	0.00025	CcSEcCtD
Diclofenac—PTGS2—Selenium Micronutrient Network—CCL2—systemic scleroderma	3.65e-05	0.00131	CbGpPWpGaD
Diclofenac—KCNQ3—Developmental Biology—MMP2—systemic scleroderma	3.64e-05	0.00131	CbGpPWpGaD
Diclofenac—KCNQ2—Developmental Biology—MMP2—systemic scleroderma	3.64e-05	0.00131	CbGpPWpGaD
Diclofenac—TTR—Disease—CD247—systemic scleroderma	3.64e-05	0.00131	CbGpPWpGaD
Diclofenac—Vision blurred—Prednisone—systemic scleroderma	3.64e-05	0.000248	CcSEcCtD
Diclofenac—Urethral disorder—Methotrexate—systemic scleroderma	3.63e-05	0.000248	CcSEcCtD
Diclofenac—Diarrhoea—Lisinopril—systemic scleroderma	3.63e-05	0.000247	CcSEcCtD
Diclofenac—Ill-defined disorder—Prednisone—systemic scleroderma	3.58e-05	0.000244	CcSEcCtD
Diclofenac—Visual impairment—Methotrexate—systemic scleroderma	3.57e-05	0.000244	CcSEcCtD
Diclofenac—Anaemia—Prednisone—systemic scleroderma	3.57e-05	0.000243	CcSEcCtD
Diclofenac—Agitation—Prednisone—systemic scleroderma	3.55e-05	0.000242	CcSEcCtD
Diclofenac—Angioedema—Prednisone—systemic scleroderma	3.52e-05	0.00024	CcSEcCtD
Diclofenac—Dizziness—Lisinopril—systemic scleroderma	3.51e-05	0.000239	CcSEcCtD
Diclofenac—Erythema multiforme—Methotrexate—systemic scleroderma	3.5e-05	0.000239	CcSEcCtD
Diclofenac—Nausea—Mycophenolic acid—systemic scleroderma	3.5e-05	0.000239	CcSEcCtD
Diclofenac—PTGS1—Selenium Micronutrient Network—IL1B—systemic scleroderma	3.48e-05	0.00125	CbGpPWpGaD
Diclofenac—Malaise—Prednisone—systemic scleroderma	3.48e-05	0.000237	CcSEcCtD
Diclofenac—Vertigo—Prednisone—systemic scleroderma	3.47e-05	0.000236	CcSEcCtD
Diclofenac—ALB—Vitamin B12 Metabolism—IL1B—systemic scleroderma	3.46e-05	0.00124	CbGpPWpGaD
Diclofenac—Eye disorder—Methotrexate—systemic scleroderma	3.46e-05	0.000236	CcSEcCtD
Diclofenac—Syncope—Prednisone—systemic scleroderma	3.46e-05	0.000236	CcSEcCtD
Diclofenac—Tinnitus—Methotrexate—systemic scleroderma	3.45e-05	0.000236	CcSEcCtD
Diclofenac—Cardiac disorder—Methotrexate—systemic scleroderma	3.44e-05	0.000235	CcSEcCtD
Diclofenac—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	3.42e-05	0.000233	CcSEcCtD
Diclofenac—Loss of consciousness—Prednisone—systemic scleroderma	3.39e-05	0.000231	CcSEcCtD
Diclofenac—CXCL8—Signaling by GPCR—RHOB—systemic scleroderma	3.38e-05	0.00121	CbGpPWpGaD
Diclofenac—Vomiting—Lisinopril—systemic scleroderma	3.37e-05	0.00023	CcSEcCtD
Diclofenac—CXCL8—GPCR ligand binding—EDN1—systemic scleroderma	3.36e-05	0.00121	CbGpPWpGaD
Diclofenac—Angiopathy—Methotrexate—systemic scleroderma	3.36e-05	0.000229	CcSEcCtD
Diclofenac—Immune system disorder—Methotrexate—systemic scleroderma	3.35e-05	0.000228	CcSEcCtD
Diclofenac—Rash—Lisinopril—systemic scleroderma	3.34e-05	0.000228	CcSEcCtD
Diclofenac—Convulsion—Prednisone—systemic scleroderma	3.34e-05	0.000228	CcSEcCtD
Diclofenac—Dermatitis—Lisinopril—systemic scleroderma	3.34e-05	0.000228	CcSEcCtD
Diclofenac—Mediastinal disorder—Methotrexate—systemic scleroderma	3.34e-05	0.000228	CcSEcCtD
Diclofenac—Asthenia—Mycophenolate mofetil—systemic scleroderma	3.33e-05	0.000227	CcSEcCtD
Diclofenac—Hypertension—Prednisone—systemic scleroderma	3.33e-05	0.000227	CcSEcCtD
Diclofenac—Chills—Methotrexate—systemic scleroderma	3.32e-05	0.000227	CcSEcCtD
Diclofenac—Headache—Lisinopril—systemic scleroderma	3.32e-05	0.000227	CcSEcCtD
Diclofenac—ABCC1—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	3.3e-05	0.00118	CbGpPWpGaD
Diclofenac—Pruritus—Mycophenolate mofetil—systemic scleroderma	3.29e-05	0.000224	CcSEcCtD
Diclofenac—Arthralgia—Prednisone—systemic scleroderma	3.28e-05	0.000224	CcSEcCtD
Diclofenac—Myalgia—Prednisone—systemic scleroderma	3.28e-05	0.000224	CcSEcCtD
Diclofenac—Anxiety—Prednisone—systemic scleroderma	3.27e-05	0.000223	CcSEcCtD
Diclofenac—Alopecia—Methotrexate—systemic scleroderma	3.27e-05	0.000223	CcSEcCtD
Diclofenac—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	3.26e-05	0.000223	CcSEcCtD
Diclofenac—Discomfort—Prednisone—systemic scleroderma	3.24e-05	0.000221	CcSEcCtD
Diclofenac—Mental disorder—Methotrexate—systemic scleroderma	3.24e-05	0.000221	CcSEcCtD
Diclofenac—Malnutrition—Methotrexate—systemic scleroderma	3.22e-05	0.00022	CcSEcCtD
Diclofenac—Erythema—Methotrexate—systemic scleroderma	3.22e-05	0.00022	CcSEcCtD
Diclofenac—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TGFB1—systemic scleroderma	3.2e-05	0.00115	CbGpPWpGaD
Diclofenac—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	3.18e-05	0.000217	CcSEcCtD
Diclofenac—Dysgeusia—Methotrexate—systemic scleroderma	3.16e-05	0.000215	CcSEcCtD
Diclofenac—Nausea—Lisinopril—systemic scleroderma	3.15e-05	0.000215	CcSEcCtD
Diclofenac—Anaphylactic shock—Prednisone—systemic scleroderma	3.15e-05	0.000215	CcSEcCtD
Diclofenac—Oedema—Prednisone—systemic scleroderma	3.15e-05	0.000215	CcSEcCtD
Diclofenac—Infection—Prednisone—systemic scleroderma	3.13e-05	0.000213	CcSEcCtD
Diclofenac—Back pain—Methotrexate—systemic scleroderma	3.12e-05	0.000213	CcSEcCtD
Diclofenac—Shock—Prednisone—systemic scleroderma	3.1e-05	0.000211	CcSEcCtD
Diclofenac—CXCL8—Metabolism of proteins—ACE—systemic scleroderma	3.09e-05	0.00111	CbGpPWpGaD
Diclofenac—Nervous system disorder—Prednisone—systemic scleroderma	3.09e-05	0.000211	CcSEcCtD
Diclofenac—Tachycardia—Prednisone—systemic scleroderma	3.07e-05	0.00021	CcSEcCtD
Diclofenac—Dizziness—Mycophenolate mofetil—systemic scleroderma	3.07e-05	0.00021	CcSEcCtD
Diclofenac—Skin disorder—Prednisone—systemic scleroderma	3.06e-05	0.000209	CcSEcCtD
Diclofenac—Hyperhidrosis—Prednisone—systemic scleroderma	3.04e-05	0.000208	CcSEcCtD
Diclofenac—Vision blurred—Methotrexate—systemic scleroderma	3.04e-05	0.000207	CcSEcCtD
Diclofenac—TTR—Extracellular matrix organization—TGFB1—systemic scleroderma	3.04e-05	0.00109	CbGpPWpGaD
Diclofenac—CXCL8—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	3.02e-05	0.00108	CbGpPWpGaD
Diclofenac—Anorexia—Prednisone—systemic scleroderma	3e-05	0.000205	CcSEcCtD
Diclofenac—Ill-defined disorder—Methotrexate—systemic scleroderma	2.99e-05	0.000204	CcSEcCtD
Diclofenac—Anaemia—Methotrexate—systemic scleroderma	2.98e-05	0.000203	CcSEcCtD
Diclofenac—TTR—Signaling Pathways—RHOB—systemic scleroderma	2.97e-05	0.00107	CbGpPWpGaD
Diclofenac—PLA2G2A—Metabolism—CTGF—systemic scleroderma	2.96e-05	0.00106	CbGpPWpGaD
Diclofenac—Vomiting—Mycophenolate mofetil—systemic scleroderma	2.95e-05	0.000201	CcSEcCtD
Diclofenac—ALB—Selenium Micronutrient Network—CCL2—systemic scleroderma	2.95e-05	0.00106	CbGpPWpGaD
Diclofenac—Rash—Mycophenolate mofetil—systemic scleroderma	2.93e-05	0.0002	CcSEcCtD
Diclofenac—Dermatitis—Mycophenolate mofetil—systemic scleroderma	2.93e-05	0.0002	CcSEcCtD
Diclofenac—Headache—Mycophenolate mofetil—systemic scleroderma	2.91e-05	0.000199	CcSEcCtD
Diclofenac—SCN4A—Axon guidance—MMP9—systemic scleroderma	2.91e-05	0.00104	CbGpPWpGaD
Diclofenac—Malaise—Methotrexate—systemic scleroderma	2.91e-05	0.000198	CcSEcCtD
Diclofenac—Vertigo—Methotrexate—systemic scleroderma	2.9e-05	0.000198	CcSEcCtD
Diclofenac—Leukopenia—Methotrexate—systemic scleroderma	2.89e-05	0.000197	CcSEcCtD
Diclofenac—PTGS2—Spinal Cord Injury—CCL2—systemic scleroderma	2.88e-05	0.00104	CbGpPWpGaD
Diclofenac—Musculoskeletal discomfort—Prednisone—systemic scleroderma	2.87e-05	0.000196	CcSEcCtD
Diclofenac—ALOX5—Metabolism—HSPG2—systemic scleroderma	2.86e-05	0.00103	CbGpPWpGaD
Diclofenac—Insomnia—Prednisone—systemic scleroderma	2.85e-05	0.000194	CcSEcCtD
Diclofenac—Paraesthesia—Prednisone—systemic scleroderma	2.83e-05	0.000193	CcSEcCtD
Diclofenac—ALB—Folate Metabolism—IL1B—systemic scleroderma	2.82e-05	0.00101	CbGpPWpGaD
Diclofenac—Cough—Methotrexate—systemic scleroderma	2.81e-05	0.000192	CcSEcCtD
Diclofenac—TTR—Signaling Pathways—HSPG2—systemic scleroderma	2.81e-05	0.00101	CbGpPWpGaD
Diclofenac—Convulsion—Methotrexate—systemic scleroderma	2.79e-05	0.000191	CcSEcCtD
Diclofenac—PTGS1—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	2.79e-05	0.001	CbGpPWpGaD
Diclofenac—Dyspepsia—Prednisone—systemic scleroderma	2.77e-05	0.000189	CcSEcCtD
Diclofenac—PTGS2—Selenium Micronutrient Network—IL1B—systemic scleroderma	2.77e-05	0.000993	CbGpPWpGaD
Diclofenac—SCN4A—Developmental Biology—MMP2—systemic scleroderma	2.76e-05	0.000992	CbGpPWpGaD
Diclofenac—Nausea—Mycophenolate mofetil—systemic scleroderma	2.76e-05	0.000188	CcSEcCtD
Diclofenac—Arthralgia—Methotrexate—systemic scleroderma	2.74e-05	0.000187	CcSEcCtD
Diclofenac—Chest pain—Methotrexate—systemic scleroderma	2.74e-05	0.000187	CcSEcCtD
Diclofenac—Myalgia—Methotrexate—systemic scleroderma	2.74e-05	0.000187	CcSEcCtD
Diclofenac—KCNQ3—Developmental Biology—MMP9—systemic scleroderma	2.74e-05	0.000984	CbGpPWpGaD
Diclofenac—KCNQ2—Developmental Biology—MMP9—systemic scleroderma	2.74e-05	0.000984	CbGpPWpGaD
Diclofenac—Decreased appetite—Prednisone—systemic scleroderma	2.74e-05	0.000187	CcSEcCtD
Diclofenac—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	2.73e-05	0.000186	CcSEcCtD
Diclofenac—UGT2B7—NRF2 pathway—TGFB1—systemic scleroderma	2.73e-05	0.000979	CbGpPWpGaD
Diclofenac—Fatigue—Prednisone—systemic scleroderma	2.71e-05	0.000185	CcSEcCtD
Diclofenac—Discomfort—Methotrexate—systemic scleroderma	2.71e-05	0.000185	CcSEcCtD
Diclofenac—TTR—Signaling Pathways—CSK—systemic scleroderma	2.71e-05	0.000973	CbGpPWpGaD
Diclofenac—Constipation—Prednisone—systemic scleroderma	2.69e-05	0.000184	CcSEcCtD
Diclofenac—Confusional state—Methotrexate—systemic scleroderma	2.65e-05	0.000181	CcSEcCtD
Diclofenac—Anaphylactic shock—Methotrexate—systemic scleroderma	2.63e-05	0.00018	CcSEcCtD
Diclofenac—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—systemic scleroderma	2.63e-05	0.000944	CbGpPWpGaD
Diclofenac—Infection—Methotrexate—systemic scleroderma	2.61e-05	0.000178	CcSEcCtD
Diclofenac—CXCR1—Signaling by GPCR—CCL2—systemic scleroderma	2.61e-05	0.000938	CbGpPWpGaD
Diclofenac—Feeling abnormal—Prednisone—systemic scleroderma	2.59e-05	0.000177	CcSEcCtD
Diclofenac—Nervous system disorder—Methotrexate—systemic scleroderma	2.58e-05	0.000176	CcSEcCtD
Diclofenac—CXCL8—Signaling Pathways—SMAD7—systemic scleroderma	2.58e-05	0.000926	CbGpPWpGaD
Diclofenac—Thrombocytopenia—Methotrexate—systemic scleroderma	2.58e-05	0.000176	CcSEcCtD
Diclofenac—Gastrointestinal pain—Prednisone—systemic scleroderma	2.57e-05	0.000176	CcSEcCtD
Diclofenac—ABCC4—NRF2 pathway—TGFB1—systemic scleroderma	2.56e-05	0.00092	CbGpPWpGaD
Diclofenac—Skin disorder—Methotrexate—systemic scleroderma	2.56e-05	0.000174	CcSEcCtD
Diclofenac—Hyperhidrosis—Methotrexate—systemic scleroderma	2.54e-05	0.000174	CcSEcCtD
Diclofenac—Anorexia—Methotrexate—systemic scleroderma	2.51e-05	0.000171	CcSEcCtD
Diclofenac—Urticaria—Prednisone—systemic scleroderma	2.5e-05	0.000171	CcSEcCtD
Diclofenac—ABCC1—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	2.5e-05	0.000898	CbGpPWpGaD
Diclofenac—Abdominal pain—Prednisone—systemic scleroderma	2.49e-05	0.00017	CcSEcCtD
Diclofenac—Body temperature increased—Prednisone—systemic scleroderma	2.49e-05	0.00017	CcSEcCtD
Diclofenac—Hypotension—Methotrexate—systemic scleroderma	2.46e-05	0.000168	CcSEcCtD
Diclofenac—ABCC1—Disease—SMAD7—systemic scleroderma	2.4e-05	0.000863	CbGpPWpGaD
Diclofenac—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	2.4e-05	0.000164	CcSEcCtD
Diclofenac—Insomnia—Methotrexate—systemic scleroderma	2.38e-05	0.000162	CcSEcCtD
Diclofenac—Paraesthesia—Methotrexate—systemic scleroderma	2.36e-05	0.000161	CcSEcCtD
Diclofenac—Dyspnoea—Methotrexate—systemic scleroderma	2.35e-05	0.00016	CcSEcCtD
Diclofenac—Somnolence—Methotrexate—systemic scleroderma	2.34e-05	0.00016	CcSEcCtD
Diclofenac—Hypersensitivity—Prednisone—systemic scleroderma	2.32e-05	0.000158	CcSEcCtD
Diclofenac—Dyspepsia—Methotrexate—systemic scleroderma	2.32e-05	0.000158	CcSEcCtD
Diclofenac—CXCL8—GPCR ligand binding—CCL2—systemic scleroderma	2.3e-05	0.000825	CbGpPWpGaD
Diclofenac—Decreased appetite—Methotrexate—systemic scleroderma	2.29e-05	0.000156	CcSEcCtD
Diclofenac—Gastrointestinal disorder—Methotrexate—systemic scleroderma	2.27e-05	0.000155	CcSEcCtD
Diclofenac—Fatigue—Methotrexate—systemic scleroderma	2.27e-05	0.000155	CcSEcCtD
Diclofenac—Asthenia—Prednisone—systemic scleroderma	2.26e-05	0.000154	CcSEcCtD
Diclofenac—CXCR1—Signaling Pathways—EDN1—systemic scleroderma	2.26e-05	0.000811	CbGpPWpGaD
Diclofenac—KCNQ3—Developmental Biology—TGFB1—systemic scleroderma	2.26e-05	0.000811	CbGpPWpGaD
Diclofenac—KCNQ2—Developmental Biology—TGFB1—systemic scleroderma	2.26e-05	0.000811	CbGpPWpGaD
Diclofenac—Pain—Methotrexate—systemic scleroderma	2.25e-05	0.000154	CcSEcCtD
Diclofenac—ALB—Selenium Micronutrient Network—IL1B—systemic scleroderma	2.24e-05	0.000804	CbGpPWpGaD
Diclofenac—ALB—Hemostasis—SELP—systemic scleroderma	2.23e-05	0.000802	CbGpPWpGaD
Diclofenac—Pruritus—Prednisone—systemic scleroderma	2.23e-05	0.000152	CcSEcCtD
Diclofenac—UGT1A1—NRF2 pathway—TGFB1—systemic scleroderma	2.21e-05	0.000795	CbGpPWpGaD
Diclofenac—PTGS2—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	2.21e-05	0.000795	CbGpPWpGaD
Diclofenac—ABCC1—Disease—TGFBI—systemic scleroderma	2.2e-05	0.00079	CbGpPWpGaD
Diclofenac—PTGS2—Spinal Cord Injury—IL1B—systemic scleroderma	2.19e-05	0.000785	CbGpPWpGaD
Diclofenac—ALOX5—Metabolism—CTGF—systemic scleroderma	2.17e-05	0.000779	CbGpPWpGaD
Diclofenac—Feeling abnormal—Methotrexate—systemic scleroderma	2.17e-05	0.000148	CcSEcCtD
Diclofenac—Diarrhoea—Prednisone—systemic scleroderma	2.15e-05	0.000147	CcSEcCtD
Diclofenac—Gastrointestinal pain—Methotrexate—systemic scleroderma	2.15e-05	0.000147	CcSEcCtD
Diclofenac—ABCB1—Allograft Rejection—IL1B—systemic scleroderma	2.14e-05	0.000768	CbGpPWpGaD
Diclofenac—PTGS1—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	2.11e-05	0.000759	CbGpPWpGaD
Diclofenac—Urticaria—Methotrexate—systemic scleroderma	2.09e-05	0.000143	CcSEcCtD
Diclofenac—ALB—Hemostasis—RHOB—systemic scleroderma	2.09e-05	0.000749	CbGpPWpGaD
Diclofenac—Dizziness—Prednisone—systemic scleroderma	2.08e-05	0.000142	CcSEcCtD
Diclofenac—Abdominal pain—Methotrexate—systemic scleroderma	2.08e-05	0.000142	CcSEcCtD
Diclofenac—Body temperature increased—Methotrexate—systemic scleroderma	2.08e-05	0.000142	CcSEcCtD
Diclofenac—SCN4A—Developmental Biology—MMP9—systemic scleroderma	2.08e-05	0.000745	CbGpPWpGaD
Diclofenac—PTGS2—Spinal Cord Injury—MMP9—systemic scleroderma	2.06e-05	0.000741	CbGpPWpGaD
Diclofenac—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—systemic scleroderma	2.04e-05	0.000734	CbGpPWpGaD
Diclofenac—Vomiting—Prednisone—systemic scleroderma	2e-05	0.000137	CcSEcCtD
Diclofenac—CXCL8—Signaling Pathways—RHOB—systemic scleroderma	2e-05	0.000717	CbGpPWpGaD
Diclofenac—CXCL8—Metabolism of proteins—MMP1—systemic scleroderma	1.99e-05	0.000714	CbGpPWpGaD
Diclofenac—Rash—Prednisone—systemic scleroderma	1.99e-05	0.000135	CcSEcCtD
Diclofenac—Dermatitis—Prednisone—systemic scleroderma	1.98e-05	0.000135	CcSEcCtD
Diclofenac—ABCC4—Hemostasis—MMP1—systemic scleroderma	1.98e-05	0.00071	CbGpPWpGaD
Diclofenac—Headache—Prednisone—systemic scleroderma	1.97e-05	0.000135	CcSEcCtD
Diclofenac—CYP1A1—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	1.96e-05	0.000705	CbGpPWpGaD
Diclofenac—Hypersensitivity—Methotrexate—systemic scleroderma	1.94e-05	0.000132	CcSEcCtD
Diclofenac—CYP2C18—Metabolism—HSPG2—systemic scleroderma	1.93e-05	0.000692	CbGpPWpGaD
Diclofenac—ALB—Hemostasis—CSK—systemic scleroderma	1.9e-05	0.000682	CbGpPWpGaD
Diclofenac—CXCL8—GPCR downstream signaling—EDN1—systemic scleroderma	1.9e-05	0.000682	CbGpPWpGaD
Diclofenac—Asthenia—Methotrexate—systemic scleroderma	1.89e-05	0.000129	CcSEcCtD
Diclofenac—CXCL8—Signaling Pathways—HSPG2—systemic scleroderma	1.88e-05	0.000676	CbGpPWpGaD
Diclofenac—ALB—Platelet degranulation—TGFB1—systemic scleroderma	1.88e-05	0.000674	CbGpPWpGaD
Diclofenac—UGT2B7—Metabolism—HSPG2—systemic scleroderma	1.87e-05	0.000673	CbGpPWpGaD
Diclofenac—Nausea—Prednisone—systemic scleroderma	1.87e-05	0.000128	CcSEcCtD
Diclofenac—Pruritus—Methotrexate—systemic scleroderma	1.86e-05	0.000127	CcSEcCtD
Diclofenac—ABCC4—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	1.84e-05	0.000661	CbGpPWpGaD
Diclofenac—CXCL8—Signaling Pathways—CSK—systemic scleroderma	1.82e-05	0.000653	CbGpPWpGaD
Diclofenac—CYP2C8—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	1.8e-05	0.000647	CbGpPWpGaD
Diclofenac—Diarrhoea—Methotrexate—systemic scleroderma	1.8e-05	0.000123	CcSEcCtD
Diclofenac—ALB—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	1.79e-05	0.000643	CbGpPWpGaD
Diclofenac—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—systemic scleroderma	1.79e-05	0.000642	CbGpPWpGaD
Diclofenac—ALB—Hemostasis—ITGAM—systemic scleroderma	1.79e-05	0.000641	CbGpPWpGaD
Diclofenac—ABCC1—Disease—HSPG2—systemic scleroderma	1.75e-05	0.00063	CbGpPWpGaD
Diclofenac—Dizziness—Methotrexate—systemic scleroderma	1.74e-05	0.000119	CcSEcCtD
Diclofenac—CXCL8—Signaling by GPCR—EDN1—systemic scleroderma	1.72e-05	0.000619	CbGpPWpGaD
Diclofenac—SCN4A—Developmental Biology—TGFB1—systemic scleroderma	1.71e-05	0.000614	CbGpPWpGaD
Diclofenac—PTGS2—Spinal Cord Injury—TGFB1—systemic scleroderma	1.7e-05	0.00061	CbGpPWpGaD
Diclofenac—ABCC1—Disease—CSK—systemic scleroderma	1.69e-05	0.000608	CbGpPWpGaD
Diclofenac—PTGS2—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	1.68e-05	0.000602	CbGpPWpGaD
Diclofenac—Vomiting—Methotrexate—systemic scleroderma	1.67e-05	0.000114	CcSEcCtD
Diclofenac—ABCB1—Allograft Rejection—TGFB1—systemic scleroderma	1.66e-05	0.000596	CbGpPWpGaD
Diclofenac—Rash—Methotrexate—systemic scleroderma	1.66e-05	0.000113	CcSEcCtD
Diclofenac—Dermatitis—Methotrexate—systemic scleroderma	1.66e-05	0.000113	CcSEcCtD
Diclofenac—Headache—Methotrexate—systemic scleroderma	1.65e-05	0.000112	CcSEcCtD
Diclofenac—CXCL8—Metabolism of proteins—CCL2—systemic scleroderma	1.62e-05	0.00058	CbGpPWpGaD
Diclofenac—PTGS2—Disease—SMAD7—systemic scleroderma	1.61e-05	0.000579	CbGpPWpGaD
Diclofenac—CYP2C19—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	1.61e-05	0.000577	CbGpPWpGaD
Diclofenac—ABCC1—Disease—CD247—systemic scleroderma	1.59e-05	0.000572	CbGpPWpGaD
Diclofenac—Nausea—Methotrexate—systemic scleroderma	1.56e-05	0.000107	CcSEcCtD
Diclofenac—CXCR1—Signaling Pathways—CCL2—systemic scleroderma	1.54e-05	0.000554	CbGpPWpGaD
Diclofenac—CXCL8—Metabolism of proteins—MMP2—systemic scleroderma	1.54e-05	0.000552	CbGpPWpGaD
Diclofenac—UGT1A1—Metabolism—HSPG2—systemic scleroderma	1.52e-05	0.000547	CbGpPWpGaD
Diclofenac—TTR—Signaling Pathways—EDN1—systemic scleroderma	1.52e-05	0.000545	CbGpPWpGaD
Diclofenac—CYP1A1—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	1.49e-05	0.000535	CbGpPWpGaD
Diclofenac—PTGS2—Disease—TGFBI—systemic scleroderma	1.48e-05	0.00053	CbGpPWpGaD
Diclofenac—ABCC1—Metabolism—HSPG2—systemic scleroderma	1.47e-05	0.000527	CbGpPWpGaD
Diclofenac—CYP2C9—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	1.47e-05	0.000526	CbGpPWpGaD
Diclofenac—CYP2C18—Metabolism—CTGF—systemic scleroderma	1.46e-05	0.000524	CbGpPWpGaD
Diclofenac—ABCC4—Hemostasis—NOS3—systemic scleroderma	1.43e-05	0.000515	CbGpPWpGaD
Diclofenac—UGT2B7—Metabolism—CTGF—systemic scleroderma	1.42e-05	0.00051	CbGpPWpGaD
Diclofenac—CXCR1—Signaling Pathways—NOS3—systemic scleroderma	1.38e-05	0.000494	CbGpPWpGaD
Diclofenac—CYP2C8—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	1.36e-05	0.00049	CbGpPWpGaD
Diclofenac—ALB—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	1.36e-05	0.000487	CbGpPWpGaD
Diclofenac—TTR—Disease—NOS3—systemic scleroderma	1.32e-05	0.000475	CbGpPWpGaD
Diclofenac—PLA2G2A—Metabolism—NOS3—systemic scleroderma	1.29e-05	0.000462	CbGpPWpGaD
Diclofenac—CYP1A2—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	1.25e-05	0.00045	CbGpPWpGaD
Diclofenac—PTGS1—Metabolism—HSPG2—systemic scleroderma	1.24e-05	0.000446	CbGpPWpGaD
Diclofenac—CYP2C19—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	1.22e-05	0.000438	CbGpPWpGaD
Diclofenac—CXCL8—Signaling by GPCR—CCL2—systemic scleroderma	1.18e-05	0.000423	CbGpPWpGaD
Diclofenac—PTGS2—Disease—HSPG2—systemic scleroderma	1.18e-05	0.000423	CbGpPWpGaD
Diclofenac—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	1.16e-05	0.000415	CbGpPWpGaD
Diclofenac—UGT1A1—Metabolism—CTGF—systemic scleroderma	1.15e-05	0.000415	CbGpPWpGaD
Diclofenac—PTGS2—Disease—CSK—systemic scleroderma	1.14e-05	0.000408	CbGpPWpGaD
Diclofenac—ABCC1—Metabolism—CTGF—systemic scleroderma	1.11e-05	0.0004	CbGpPWpGaD
Diclofenac—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	1.11e-05	0.000399	CbGpPWpGaD
Diclofenac—CXCR1—Signaling Pathways—MMP9—systemic scleroderma	1.1e-05	0.000396	CbGpPWpGaD
Diclofenac—PTGS2—Disease—CD247—systemic scleroderma	1.07e-05	0.000384	CbGpPWpGaD
Diclofenac—TTR—Signaling Pathways—CCL2—systemic scleroderma	1.04e-05	0.000373	CbGpPWpGaD
Diclofenac—CXCL8—Signaling Pathways—EDN1—systemic scleroderma	1.02e-05	0.000366	CbGpPWpGaD
Diclofenac—PTGS2—Metabolism—HSPG2—systemic scleroderma	9.86e-06	0.000354	CbGpPWpGaD
Diclofenac—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	9.49e-06	0.000341	CbGpPWpGaD
Diclofenac—ABCC4—Hemostasis—TGFB1—systemic scleroderma	9.48e-06	0.000341	CbGpPWpGaD
Diclofenac—CYP2B6—Metabolism—HSPG2—systemic scleroderma	9.47e-06	0.00034	CbGpPWpGaD
Diclofenac—ALOX5—Metabolism—NOS3—systemic scleroderma	9.45e-06	0.000339	CbGpPWpGaD
Diclofenac—PTGS1—Metabolism—CTGF—systemic scleroderma	9.41e-06	0.000338	CbGpPWpGaD
Diclofenac—CYP2E1—Metabolism—HSPG2—systemic scleroderma	9.28e-06	0.000333	CbGpPWpGaD
Diclofenac—TTR—Signaling Pathways—NOS3—systemic scleroderma	9.25e-06	0.000332	CbGpPWpGaD
Diclofenac—CXCR1—Signaling Pathways—TGFB1—systemic scleroderma	9.09e-06	0.000327	CbGpPWpGaD
Diclofenac—ALB—Hemostasis—MMP1—systemic scleroderma	8.95e-06	0.000321	CbGpPWpGaD
Diclofenac—CYP1A1—Metabolism—HSPG2—systemic scleroderma	8.75e-06	0.000314	CbGpPWpGaD
Diclofenac—TTR—Disease—TGFB1—systemic scleroderma	8.74e-06	0.000314	CbGpPWpGaD
Diclofenac—ALB—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	8.32e-06	0.000299	CbGpPWpGaD
Diclofenac—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	8.2e-06	0.000294	CbGpPWpGaD
Diclofenac—CYP2C8—Metabolism—HSPG2—systemic scleroderma	8.02e-06	0.000288	CbGpPWpGaD
Diclofenac—ALB—Metabolism—HSPG2—systemic scleroderma	7.97e-06	0.000286	CbGpPWpGaD
Diclofenac—PTGS2—Metabolism—CTGF—systemic scleroderma	7.47e-06	0.000268	CbGpPWpGaD
Diclofenac—TTR—Signaling Pathways—MMP9—systemic scleroderma	7.42e-06	0.000267	CbGpPWpGaD
Diclofenac—CYP2B6—Metabolism—CTGF—systemic scleroderma	7.18e-06	0.000258	CbGpPWpGaD
Diclofenac—CYP2C19—Metabolism—HSPG2—systemic scleroderma	7.16e-06	0.000257	CbGpPWpGaD
Diclofenac—CYP2E1—Metabolism—CTGF—systemic scleroderma	7.03e-06	0.000253	CbGpPWpGaD
Diclofenac—ABCB1—Metabolism—HSPG2—systemic scleroderma	6.99e-06	0.000251	CbGpPWpGaD
Diclofenac—CXCL8—Signaling Pathways—CCL2—systemic scleroderma	6.96e-06	0.00025	CbGpPWpGaD
Diclofenac—CYP1A1—Metabolism—CTGF—systemic scleroderma	6.63e-06	0.000238	CbGpPWpGaD
Diclofenac—CYP2C9—Metabolism—HSPG2—systemic scleroderma	6.53e-06	0.000234	CbGpPWpGaD
Diclofenac—ALB—Hemostasis—NOS3—systemic scleroderma	6.49e-06	0.000233	CbGpPWpGaD
Diclofenac—CYP2C18—Metabolism—NOS3—systemic scleroderma	6.36e-06	0.000228	CbGpPWpGaD
Diclofenac—CXCL8—Signaling Pathways—NOS3—systemic scleroderma	6.21e-06	0.000223	CbGpPWpGaD
Diclofenac—UGT2B7—Metabolism—NOS3—systemic scleroderma	6.18e-06	0.000222	CbGpPWpGaD
Diclofenac—TTR—Signaling Pathways—TGFB1—systemic scleroderma	6.12e-06	0.00022	CbGpPWpGaD
Diclofenac—CYP2C8—Metabolism—CTGF—systemic scleroderma	6.08e-06	0.000218	CbGpPWpGaD
Diclofenac—ALB—Metabolism—CTGF—systemic scleroderma	6.04e-06	0.000217	CbGpPWpGaD
Diclofenac—ABCC1—Disease—NOS3—systemic scleroderma	5.79e-06	0.000208	CbGpPWpGaD
Diclofenac—CYP1A2—Metabolism—HSPG2—systemic scleroderma	5.58e-06	0.0002	CbGpPWpGaD
Diclofenac—CYP2C19—Metabolism—CTGF—systemic scleroderma	5.43e-06	0.000195	CbGpPWpGaD
Diclofenac—ABCB1—Metabolism—CTGF—systemic scleroderma	5.3e-06	0.00019	CbGpPWpGaD
Diclofenac—UGT1A1—Metabolism—NOS3—systemic scleroderma	5.02e-06	0.00018	CbGpPWpGaD
Diclofenac—CXCL8—Signaling Pathways—MMP9—systemic scleroderma	4.98e-06	0.000179	CbGpPWpGaD
Diclofenac—CYP2C9—Metabolism—CTGF—systemic scleroderma	4.95e-06	0.000178	CbGpPWpGaD
Diclofenac—ABCC1—Metabolism—NOS3—systemic scleroderma	4.84e-06	0.000174	CbGpPWpGaD
Diclofenac—CYP3A4—Metabolism—HSPG2—systemic scleroderma	4.3e-06	0.000155	CbGpPWpGaD
Diclofenac—ALB—Hemostasis—TGFB1—systemic scleroderma	4.29e-06	0.000154	CbGpPWpGaD
Diclofenac—CYP1A2—Metabolism—CTGF—systemic scleroderma	4.23e-06	0.000152	CbGpPWpGaD
Diclofenac—CXCL8—Signaling Pathways—TGFB1—systemic scleroderma	4.1e-06	0.000147	CbGpPWpGaD
Diclofenac—PTGS1—Metabolism—NOS3—systemic scleroderma	4.1e-06	0.000147	CbGpPWpGaD
Diclofenac—PTGS2—Disease—NOS3—systemic scleroderma	3.88e-06	0.000139	CbGpPWpGaD
Diclofenac—ABCC1—Disease—TGFB1—systemic scleroderma	3.83e-06	0.000137	CbGpPWpGaD
Diclofenac—CYP3A4—Metabolism—CTGF—systemic scleroderma	3.26e-06	0.000117	CbGpPWpGaD
Diclofenac—PTGS2—Metabolism—NOS3—systemic scleroderma	3.25e-06	0.000117	CbGpPWpGaD
Diclofenac—CYP2B6—Metabolism—NOS3—systemic scleroderma	3.13e-06	0.000112	CbGpPWpGaD
Diclofenac—CYP2E1—Metabolism—NOS3—systemic scleroderma	3.06e-06	0.00011	CbGpPWpGaD
Diclofenac—CYP1A1—Metabolism—NOS3—systemic scleroderma	2.89e-06	0.000104	CbGpPWpGaD
Diclofenac—CYP2C8—Metabolism—NOS3—systemic scleroderma	2.65e-06	9.5e-05	CbGpPWpGaD
Diclofenac—ALB—Metabolism—NOS3—systemic scleroderma	2.63e-06	9.45e-05	CbGpPWpGaD
Diclofenac—PTGS2—Disease—TGFB1—systemic scleroderma	2.57e-06	9.22e-05	CbGpPWpGaD
Diclofenac—CYP2C19—Metabolism—NOS3—systemic scleroderma	2.36e-06	8.48e-05	CbGpPWpGaD
Diclofenac—ABCB1—Metabolism—NOS3—systemic scleroderma	2.3e-06	8.28e-05	CbGpPWpGaD
Diclofenac—CYP2C9—Metabolism—NOS3—systemic scleroderma	2.15e-06	7.73e-05	CbGpPWpGaD
Diclofenac—CYP1A2—Metabolism—NOS3—systemic scleroderma	1.84e-06	6.61e-05	CbGpPWpGaD
Diclofenac—CYP3A4—Metabolism—NOS3—systemic scleroderma	1.42e-06	5.1e-05	CbGpPWpGaD
